ArticleNature communications2016
Nicotinic acetylcholine receptor agonist attenuates ILC2-dependent airway hyperreactivity.
Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 141 citations in OpenAlex.
- Neuroimmune circuits in respiratory pathophysiology: decoding molecular crosstalk for precision therapeutic targeting.Annals of medicine · 2026Review
- Neuro-immune interactions in tumors, immune-related disorders, and infections.Signal transduction and targeted therapy · 2026Review
- Activation of lung megakaryocyte α7 nAChR exacerbates allergic airway inflammation via IL-33/p38 MAPK signaling.JCI insight · 2026Article
- Article
- Mechanisms and therapeutic strategies of asthma: from bench to bedside.Signal transduction and targeted therapy · 2026Review
- Group 2 innate lymphoid cells: Where are we 15 years out?The Journal of allergy and clinical immunology · 2026Review
- Overview of allergic disease: Pathogenesis of allergic inflammation - WAO White Book on Allergy 2026 - 2.1.The World Allergy Organization journal · 2026Review
- Alpha7 nicotinic acetylcholine receptor activation attenuates allergic airway inflammation and is associated with heme oxygenase-1 induction.Frontiers in immunology · 2026Article
- The Expanding Role of ILC2s in Allergic Airways Disease.Allergy · 2026Review
- Neuroplasticity and neuroimmune interactions with type 2 inflammation in asthma.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Neurogenic regulation of group 2 innate lymphoid cells in asthma.Frontiers in immunology · 2026Review
- Melatonin suppresses ILC2-driven airway hyperreactivity via glutathione-dependent metabolic reprogramming.Frontiers in immunology · 2026Article
- Skin-lung axis in the atopic march: The immune link from skin to lungs.Chinese medical journal pulmonary and critical care medicine · 2025Review
- New Perspectives on Classical Alarmin Responses to Intestinal Helminth Infection.Parasite immunology · 2025Review
- PAI-1 Inhibitor TM5441 Attenuates Emphysema and Airway Inflammation in a Murine Model of Chronic Obstructive Pulmonary Disease.International journal of molecular sciences · 2025Article
- Touching a Nerve: Neuroimmune Interactions in Asthma.Immunological reviews · 2025Review
- Neuroimmune Circuits in Allergic Diseases.Annual review of immunology · 2025Review
- Neurogenic inflammation and itch in barrier tissues.Seminars in immunology · 2025Review
- Physiopathological Roles of White Adiposity and Gut Functions in Neuroinflammation.International journal of molecular sciences · 2024Review
- Peripheral and central regulation of neuro-immune crosstalk.Inflammation and regeneration · 2024Review
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Allergic asthma is a complex and chronic inflammatory disorder that is associated with airway hyperreactivity (AHR) and driven by Th2 cytokine secretion. Type 2 innate lymphoid cells (ILC2s) produce large amounts of Th2 cytokines and contribute to the development of AHR. Here, we show that ILC2s express the α7-nicotinic acetylcholine receptor (α7nAChR), which is thought to have an anti-inflammatory role in several inflammatory diseases. We show that engagement of a specific agonist with α7nAChR on ILC2s reduces ILC2 effector function and represses ILC2-dependent AHR, while decreasing expression of ILC2 key transcription factor GATA-3 and critical inflammatory modulator NF-κB, and reducing phosphorylation of upstream kinase IKKα/β. Additionally, the specific α7nAChR agonist reduces cytokine production and AHR in a humanized ILC2 mouse model. Collectively, our data suggest that α7nAChR expressed by ILC2s is a potential therapeutic target for the treatment of ILC2-mediated asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.